LRRC15 and sarcoma: Tumor-specific ADCs with LRRC15 expression, such as ABBV-085, are currently under testing in phase I clinical trials (NCT02565758) in sarcomas and other solid tumors, such as head and neck squamous cell carcinoma and BC [134].